Molly Gibson, PhD

Molly is Chief Executive Officer of Expedition Medicines. 

Molly is an experienced founder, technologist, and builder of AI-native platforms that expand the boundaries of scientific discovery. Prior to Expedition, as Co-Founder and President at Lila Sciences, she led the development of the AI Science Factories — a platform designed to build Scientific Superintelligence by allowing AI to run the scientific method through interaction with a physical lab. As Co-Founder and Chief Strategy & Innovation Officer at Generate: Biomedicines, she helped lead the development of one of the world’s first transformer-based models for protein design — pioneering a new approach to therapeutic creation through generative AI.

At Flagship, Molly in an Origination Partner at Flagship Pioneering, where she leads a Pioneering Business Unit focused on founding, building, and growing companies at the intersection of artificial intelligence and science. Her work has led to numerous patents and peer-reviewed publications in Science and Nature and underpins programs now advancing through clinical development.

A computer scientist by training, she earned her PhD in computational biology at Washington University in St. Louis and became recognized for her ability to unify deep scientific intuition with cutting-edge AI. Her work has been featured by The New York Times, CNBC, McKinsey & Company, and 60 Minutes, and she was named to Endpoints ​“20 under 40” shaping the future of biotech and Great Entrepreneurs Top 50 BioTech Entrepreneurs.